News

Capricor Reports 4-Year Data For Deramiocel, Shows Sustained Benefit In Duchenne Patients
Capricor shares four-year data showing Deramiocel slowed DMD progression and preserved function, with maintained safety in long-term use.
Capricor Therapeutics announces four-year data from HOPE-2 OLE study
Capricor Therapeutics (CAPR) announced four-year safety and efficacy results from its ongoing HOPE-2 Open-Label Extension study of Deramiocel, the Company’s lead cell therapy candidate for Duchenne ...
Capricor Therapeutics Announces Positive 4-Year Data from HOPE-2 Open-Label Extension Study of Deramiocel in Duchenne Muscular Dystrophy
Skeletal muscle disease progression continues to slow with extended treatment (PUL v2.0) ...
Stocktwits on MSN22h
Capricor Stock Slumps 16% On Report Of Key FDA Executive’s Removal, But Retail’s Hopeful About New 4-Year Deramiocel Data
Shares of Capricor Therapeutics (CAPR) tumbled 16% on Friday morning following reports that Nicole Verdun, director of the ...
Capricor falls after report on AdCom meeting cancellation (update)
Capricor Therapeutics (NASDAQ:CAPR) plunged 32% following a trading halt on Friday after Stat News reported that the new head ...
Capricor Therapeutics stock plunges after key FDA officials placed on leave
This leadership vacuum follows another significant departure at the FDA. Peter Marks, former head of the Center for Biologics Evaluation and Research who worked closely with Verdun on establishing new ...